INTRODUCTION
Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which both CD4 and CD8 T cells (CTLs) target insulin-producing islet b cells. In human T1D, islet-specific CTLs have been identified and histology shows CTLs in the islets, whereas in the non-obese diabetic (NOD) mouse, CTLs are implicated in the initial stages as well as in progression of disease. [1] [2] [3] [4] [5] [6] Selective immunotargeting of diabetogenic CTLs is therefore a promising avenue for immunotherapy of T1D.
The CD3-z chain is an essential signaling component of the T cell receptor (TCR) complex. T cells genetically redirected through major histocompatibility complex (MHC)-I heavy (a) chains fused with CD3-z and supplemented with a peptide of choice can target peptide-specific CD8 T cells, initially achieved through the expression of MHC-Ia/CD3-z fusion proteins. For example, T cells expressing chimeric H-2K b /CD3-z and pulsed with a distinct peptide exhibited efficient cytolysis of antigen-specific cytotoxic CTL precursors. 7 Furthermore, transgenic T cells of a unique memory phenotype expressing an H-2D d /CD3-z construct potently vetoed responses to H-2D d in vitro. 8 The addition of a cognate H-2D d peptide endowed these transgenic cells with cytolytic activity against an antigen-specific T cell hybridoma. The polymorphic MHC-I heavy chain is non-covalently associated with an invariant, non-MHC-encoded b 2 microglobulin (b 2 m) light chain, not anchored to the plasma membrane. We have shown that b 2 m can serve as a versatile molecular scaffold for chimeric MHC-I/CD3-z T cell activation receptors. 9 A single b 2 m/CD3-z-based expression cassette enables covalent linking of any pre-selected peptide to the N terminus of b 2 m, so as to redirect T cells at autoreactive CD8 T cells of a given specificity.
A number of cloned diabetogenic CTLs from the NOD mouse target identified antigens. Proinsulin is a major target antigen for diabetogenic CTLs, both in the NOD mouse 10 and in humans. [11] [12] [13] [14] [15] [16] [17] G9C8 is a highly pathogenic CTL clone that recognizes insulin B chain, amino acids 15-23 (InsB [15] [16] [17] [18] [19] [20] [21] [22] [23] in the context of H-2K d in the NOD mouse, 10, 18 and the cells are a predominant population in the early CD8 T cell infiltrate detected as early as 4 weeks of age. 10, 19 Later, CD8 T cells reactive against an H-2K d -binding peptide from islet-specific glucose-6-phosphatase catalytic subunitrelated protein, amino acids 206-214 (IGRP 206-214 ) [20] [21] [22] [23] become dominant. A third islet-reactive, pathogenic NOD CTL, although initially thought to be specific to a dystrophia myotonica kinase, amino acids 138-146 (DMK [138] [139] [140] [141] [142] [143] [144] [145] [146] ) peptide, is actually reactive to insulin. [23] [24] [25] Interestingly, the relative distribution in the infiltrate of T cells varies considerably among individual mice, defining a unique immunological signature. [20] [21] [22] [23] CD8 T cells reactive to glutamic acid decarboxylase (GAD65)-especially GAD65, amino acids 546-554 (GAD65 546-554 )-have also been identified in the NOD mouse. 26, 27 Immune responses to proinsulin are necessary for IGRP-reactive CTLs to expand 28, 29 and to cause diabetes. Therefore, early immunological intervention selectively targeting dominant CTL clones may arrest b cell destruction and inhibit, or entirely prevent, the onset of disease. As a proof of concept, we previously generated NOD mice expressing an InsB 15-23 /b 2 m/CD3-z construct in CD8 T cells. 30 CTLs from these mice killed InsB 15-23 -reactive target CD8 T cells and protected NOD SCID (severe combined immunodeficiency) mice from diabetes when co-transferred with the pathogenic T cells and significantly reduced spontaneous diabetes in wild-type NOD mice. 31 Transfection of mRNA to modify primary human and mouse T cells has drawn considerable interest. Electroporation of mRNA is fast, simple, and exceptionally efficient and drives high and uniform expression under mild conditions, thereby preserving cell viability. Although transient, mRNA transfection can drive functional expression of the introduced genes up to 5-7 days and more. [32] [33] [34] [35] [36] The use of mRNA entirely obviates the risk of cellular transformation and allows the co-introduction of several genes as pre-defined mixtures, which is often limited with other gene delivery vehicles.
Here we show that CD8 T cells can be reprogrammed to recognize diabetogenic T cells following the electroporation of mRNA encoding peptide/b 2 m/CD3-z and this can target autoreactive CTLs in vivo to reduce insulitis and prevent autoimmune diabetes in the NOD mouse. [37] [38] [39] and is useful for detecting expression of the resulting MHC-I complexes. Flow cytometric analysis confirmed the expression of hb 2 m at the cell surface of CD8 T cells purified from BALB/c and NOD mice and the reporter B3Z T cell hybridoma following mRNA transfection ( Figure 1C ). This expression was reproducible over many experiments. We then evaluated the effect of the amount of InsB 15-23 /b 2 m/CD3-z mRNA used for electroporation and level of expression in B3Z cells. Indeed, both flow cytometry and western blot analyses for hb 2 m ( Figures 1D and 1E ) revealed dose-dependent expression, which was not accompanied by a reduction in cell viability at the higher mRNA concentrations (not shown reporter gene, this assay does not discriminate between the two. However, it coincides with our previous work 31 showing two-way T cell activation mediated by the G9C8 TCR and the InsB 15-23 / b 2 m/CD3-z construct, as the G9TCR recognizes the construct and the triggering of the construct activates the transfected cell. Here we recapitulate this notion also for exogenous mRNA-driven expression.
RESULTS

Assembly
Functional Expression of Peptide/b 2 m/CD3-z in NOD CD8 T Cells
We went on to test whether polyclonal NOD CD8 T cells can be endowed with the ability to kill diabetogenic T cells following electroporation with peptide/b 2 m/CD3-z mRNA. In the experiment presented in Figure 3A , we employed CHIB2 T cell hybridomas as target cells. (effectors) were incubated with CHIB2 (targets) at three different effector-to-target (E:T) ratios and dose-dependent killing of the target CHIB2 cells was observed. We previously showed that expression of the peptide/b 2 m/anchor configuration resulted in exceptionally high occupancy of the restricting MHC-I product by the linked peptide. 9, 40 To supplement the endogenous H-2K d in the polyclonal NOD CD8 T cells, we tested the addition of mRNA encoding H-2K d heavy chains. Figure 3A illustrates that the transfected polyclonal CD8 T cells have acquired the ability to kill the target CHIB2 cells and overexpression of H-2K d had no discernible effect on the killing activity. Example flow cytometric plots are shown in Figure S1 . Figure 3B 
CD8 T Cells Redirected to Kill Insulin-Reactive CD8 T Cells Reduce Diabetes
Having shown that the redirected CD8 T cells were able to kill insulinreactive or IRGP-reactive T cells in vitro, we then tested the effect of the redirected CD8 T cells on the incidence of diabetes in vivo. CD8 T cells transfected with either InsB 15-23 /b 2 m/CD3-z or IGRP 206-214 / b 2 m/CD3-z mRNA were adoptively transferred into 5-to 6-week-old female NOD mice in a single transfer. These mice were tested weekly for glycosuria and diabetes was confirmed by a blood glucose reading of >13.9 mmol/L. The mice were euthanized either when they became diabetic or at 35 weeks if they were non-diabetic. We observed a significant reduction in the incidence of diabetes when the cells were transfected with the InsB [15] [16] [17] [18] [19] [20] [21] [22] [23] 
DISCUSSION
In this study, we have shown that mRNA constructs encoding autoantigenic peptide/b 2 m/CD3-z can be used to transfect both T cell hybrids as well as polyclonal T cells and redirect these T cells against autoreactive pathogenic CTLs. This means of selectively targeting antigen-specific cells is a modification of the successful chimeric antigen receptor (CAR) strategy adopted for tumor adoptive cell therapy 41 and could be used in adoptive cell therapy in type 1 diabetes. There is good expression of the constructs and we have shown that functionally, the redirected targeting cells are recognized specifically The simultaneous immunotargeting of a number of dominant autoreactive CD8 T cell clones by the peptide/b 2 m/CD3-z constructs can be attained either by the co-transfection of the same polyclonal CD8 T cells with a combination of mRNAs encoding the respective peptide/b 2 m/CD3-z polypeptides or the co-administration of a mixture of T cell transfectants, each of which expresses a different peptide/b 2 m/CD3-z mRNA. In the current study, we have demonstrated the functional expression of the different mRNA species, each co-transfected (when needed) with mRNA encoding the H-2K d heavy chain (Figure 2A ). In this experiment, the activation of transfectants by MHC-I cross-linking required the functional expression and pairing of the polypeptide products of both mRNA encoding MHC-I as well as the peptide/b 2 m/CD3-z. Nevertheless, it was almost as powerful as cellular activation triggered by TCR cross-linking under exactly the same conditions. In an accompanying study, 42 we recently showed that mRNA encoding peptide/MHC-II/ CD3-z can be similarly used to efficiently redirect T cells against pathogenic CD4 T cells in a peptide-specific manner. Likewise, in that study, T cell activation through the chimeric MHC-II molecules, which also required co-expression and pairing of the two products, was comparable to TCR-mediated activation. The current achievement complements our arsenal of genetic immunotargeting devices against both CD4 and CD8 islet-reactive T cells in the NOD mouse.
The demonstration that redirected polyclonal NOD CD8 T cells kill autoreactive CD8 T cells (Figure 3 ) recapitulates our previous findings 31 in which the insulin-reactive CD8 T cells were killed by preactivated T cells that expressed InsB 15-23 /b 2 m/CD3-z as a transgene.
However, while those transgenic experiments illustrated the principle that CD8 T cells could be effectively redirected to kill antigen-specific targets, this procedure would not be translatable for immunotherapy in humans. In the current study, the strategy brings the procedure a step nearer to translation, in that we have shown that primary cells can be readily transfected with the mRNA construct and can kill insulin-reactive targets in a similar manner.
When the InsB 15-23 /b 2 m/CD3-z or IGRP 206-214 /b 2 m/CD3-z mRNAtransfected cells were transferred to young NOD female mice, protection from diabetes was only seen when the cells targeted InsB 15-23 -reactive T cells. The injection was done at a time (5-6 weeks of age) when insulin-reactive cells are detected in the pancreatic lymph nodes in a higher proportion than at later time points. In contrast, IGRP-reactive T cells tend to rise later on, so that injecting the cells at this young age may be more likely to target insulin-reactive T cells. 10, 19 In principle, cell transfer aiming at immunotargeting T cells of both autoreactivities can be carried out at different time points, so that the earlier transfer targets insulin-reactive T cells and the later one targets IGRP-reactive cells. The current study demonstrates proof of principle and further studies will be carried out in the future to optimize timing of injections, including injections at later time points and whether more than one adoptive cell transfer may be required.
To our knowledge, this work is the first demonstration that mRNAtransfected T cells expressing chimeric MHC complexes can selectively immunotarget pathogenic T cells in vivo and inhibit or reduce the incidence of autoimmune diabetes. We are also evaluating the similar reprogramming of regulatory T cells in an ongoing study, hypothesizing that the targeting of a narrow population of autoreactive CD8 or CD4 T cell clones may suffice for eliciting a broad tolerizing effect. 
MATERIALS AND METHODS
DNA Vectors and Plasmids
The pGEMT vector for direct cloning of PCR products was from Promega. Template DNA for in vitro transcription of mRNA was cloned into the pGEM4Z/GFP/A64 vector, 43 a kind gift from Dr. E.
Gilboa (University of Miami) following the removal of the GFP insert (pGEM4Z/A64).
Assembly of Genetic Constructs
All PCR products were sub-cloned and their DNA sequence was confirmed prior to insertion in expression vectors. For cloning of the four constructs encoding peptide/human b 2 m/mouse CD3-z, we used essentially the same cloning strategy we described previously. 9 The gene segment encoding the full leader sequence of human were inserted into pGEM4Z/A64.
Cell Lines
B3Z
45 is an ovalbumin (OVA) 257-264 -specific, H-2K b -restricted CTL hybridoma and was a kind gift from Dr. N. Shastri (University of California, Berkeley). CHIB2 is an InsB [15] [16] [17] [18] [19] [20] [21] [22] [23] -specific hybrid of the G9C8 T cell clone with the BW5147 thymoma expressing CD8, H-2K d -restricted T cell hybridoma. 10 Both B3Z and CHIB2 harbor the nuclear factor of activated T cells-lacZ inducible reporter gene.
In Vitro Transcription and Electroporation of mRNA
Template DNA cloned in pGEM4Z/A64 was prepared with the EndoFree Plasmid Maxi Kit (Promega) and linearized using the SpeI restriction site positioned at the 3 0 end of the poly(A) tract of the vector. In vitro transcription was conducted in a 20-mL reaction mix at 37 C using the T7 mScript Standard mRNA Production System (CellScript) to generate 5 0 -capped in vitro-transcribed mRNA. Cells were washed twice with OptiMEM medium (Gibco) and re-suspended in 200 mL OptiMEM containing the required amount of in vitro-transcribed mRNA (10-20 mg in most experiments). Electroporation was performed with Gene Pulser Xcell (Bio-Rad Laboratories) in 2-mm cuvettes using a square wave pulse (1 millisecond, 300 V) for the experiments with cell lines, or with BTX Harvard Apparatus ECM830 (1 millisecond, 300 V) for the primary cells.
Mice NOD mice, originally from the NOD/CaJ colony at Yale University, and G9 TCR transgenic mice 47 have been bred at Cardiff University for 5 years. NY8.3 TCR transgenic mice 48 were purchased from Jackson Laboratory. These mice were housed in microisolators at the specific pathogen-free facility at Cardiff University. BALB/c mice were maintained at the animal facility of the Bar-Ilan University Faculty of Medicine. All procedures were performed in accordance with protocols approved by the UK Home Office and the Israeli National Committee Institutional Animal Care and Use Committee.
Antibodies and Reagents
Anti-H-2K d monoclonal antibody (mAb) (clone SF1-1.1) was from Pharmingen and anti-H-2D b mAb was purified from the supernatant of the 28-14-8 hybridoma. 2C11 is a hamster mAb specific to mouse CD3ε. mAb against hb 2 m (clone BM-63) was from Sigma. Rabbit polyclonal antibodies against hb 2 m were from Dako. Hamster mAb to mouse CD3z (clone H146-968) was from Santa Cruz Biotechnology. Horseradish peroxidase (HRP)-conjugated goat antibodies against rabbit IgG were from Jackson Laboratory. Rabbit antibodies against hamster IgG and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG and FITC-conjugated donkey anti-mouse IgG were from Sigma and Jackson Laboratory, respectively. HRPconjugated rabbit antibodies against hamster IgG were from Sigma. Biotinylated rat anti-mouse CD4 (clone GK1.5) was purchased from Biolegend. Biotinylated rat anti-mouse CD8a (clone 53-6.7) and rat anti-mouse B220 (clone RA3-6B2) were from BD Pharmingen and biotinylated mouse anti-insulin antibody (ICBTACLS) was from eBioscience.
Flow Cytometry
One million cultured cells or primary cells harvested from the spleen of mice were used. Single cell suspensions were either stained with the respective monoclonal antibodies in a direct staining procedure or, for indirect staining, the cells were incubated with the primary antibody for 1 hr and then washed before further incubation with fluorophore-labeled secondary antibody at 4 C. Cells were washed twice, resuspended in 1 mL cold PBS, and analyzed by a FACSCalibur or FACSCanto system (Becton Dickinson). Data were analyzed by FCS Express (version 4; De Novo Software) or FlowJo (version 7.6.5; Tree Star) software.
Chlorophenol Red b-D-Galactopyranoside Assay B3Z transfected cells were incubated in plates coated with immobilized MHC-I antibody or with CHIB2 hybridoma cells overnight. The culture medium was removed and 100 mL lysis buffer (9 mM MgCl 2 , 0.125% NP-40, and 0.3 mM chlorophenol red b-D-galactopyranoside [CPRG] in PBS) was added to each well. One to 24 hr post-lysis, the optical density (OD) of each well was measured using an ELISA reader (at 570 nm, with 630 nm as reference).
Immunoblot Analysis
Protein samples were boiled for 3 minutes, separated on a 10% nonreducing SDS polyacrylamide gel at 50 mA, and transferred onto a nitrocellulose membrane. The membrane was blocked with milk buffer (0.3 g Na 2 HPO 4 , 2.19 g NaCl, 25 mL water, and 225 mL 1% low-fat milk) overnight at 4 C and 1 hr at room temperature, washed twice with PBS, and incubated for 2 hr with the primary antibody. The membrane was then washed six times for 6 min with PBS, incubated for 1 hr with the secondary peroxidase-conjugated antibody, washed six times for 6 min with TPBS (PBS with 0.05% Tween 20), washed six times for 6 min with PBS, and then developed using an ECL (enhanced chemiluminescence) kit (Pierce-Thermo Fisher Scientific) and X-ray film 100NIF (Fuji).
Cytotoxicity Assay
CD8 T cells were isolated from the spleen of 5-to 6-week-old NOD mice and separated by negative selection (MACS; Miltenyi Biotec). The purified CD8 T cells were then activated and expanded by stimulation using plate-bound anti-CD3 and anti-CD28 antibodies, interleukin (IL)-2 and IL-7 as previously described. 49 The activated CD8
T cells were transfected with mRNA encoding InsB 15-23 /b 2 m/CD3-z or IGRP 206-214 /b 2 m/CD3-z. These cells were the effector cells of the assay. G9 and NY8.3 TCR transgenic CD8 + T cells were purified by negative selection (MACS; Miltenyi Biotec) from the spleens of G9 and NY8.3 transgenic mice, respectively. Activated mRNA-transfected T cells (effectors) were incubated with purified G9 or NY8.3 T cells (targets), labeled with PKH-26 (Sigma), at an effector-to-target ratio of 1:1 and 5:1 for 16 hr at 37 C. To detect cell death, TO-PRO-3 iodide (Thermo Fisher Scientific) was added immediately prior to flow cytometric analysis. Single PKH-26 + TO-PRO-3 + cells were gated, and cytotoxicity was expressed as the percentage of dead cells/total targets. 31 Activated CD8 T cells with no transfected mRNA served as controls for the effector T cells.
Adoptive Transfer
NOD CD8 T cells were isolated, activated, expanded, and transfected with mRNA as described for the cytotoxicity assay. As a control, CD8+ T cells were subjected to the electroporation procedure but with no added mRNA (mock transfection). Transfected cells (peptide/b 2 m/CD3-z construct and mock-transfected) were adoptively transferred into 6-week-old NOD mice recipients by injection into the tail vein (6-10 Â 10 6 cells per mouse).
Diagnosis of Diabetes
Mice were screened weekly for glycosuria (Diastix; Bayer) and, following two consecutive positive readings, diabetes was confirmed by a blood glucose reading of >13.9 mmol/L.
Histology
The pancreas was fixed in paraformaldehyde lysine periodate buffer overnight and then infused with 10% sucrose followed by 20% sucrose, as previously described. 31 The pancreas was then embedded in OCT and snap frozen for immunohistochemistry. Frozen sections of 10-mm thickness were cut and stained with rat anti-mouse CD4, CD8, B220, and anti-insulin antibodies and detected with streptavidin-alkaline phosphatase and a Vector Red AP substrate kit (Vector Laboratories). The sections were counter-stained with hematoxylin. Insulitis was assessed from at least three mice per group and 80-115 islets were scored. Scoring for insulitis is shown in the legend for Figure 4 .
Statistical Analysis
Log-rank analysis was carried out for the adoptive transfer experiments. The c 2 test was performed for the analysis of insulitis. For all tests, p < 0.05 was considered statistically significant.
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